IOL Chemicals & Pharmaceuticals reported a robust start to FY26, with standalone net profit rising 89.9% year-on-year to ₹64.48 crore for the quarter ended June 30, 2026. The chemical manufacturer’s total income from operations expanded to ₹764.44 crore, up from ₹559.06 crore in Q1FY25, reflecting strong top-line momentum and improved operational efficiency across its business segments.

The results were approved by the Board of Directors at their meeting held on August 10, 2026, following review by the Audit Committee. The unaudited financial results were published in Business Standard, Economic Times, Financial Express, and Punjabi Jagran on August 11, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory Auditors expressed an unmodified opinion on these results after a limited review.

Financial Performance Overview

IOL Chemicals & Pharmaceuticals demonstrated significant growth in both revenue and profitability metrics during the quarter. The company’s net profit before tax stood at ₹86.77 crore, compared to ₹45.54 crore in the corresponding period of the previous year. This improvement was underpinned by a substantial increase in total income from operations, which grew by approximately 36.7% year-on-year.

On a consolidated basis, the net profit after tax was ₹64.40 crore, compared to ₹33.93 crore in Q1FY25. Consolidated total income from operations remained consistent with standalone figures at ₹764.44 crore for the quarter.

Profitability and Operational Efficiency

The near-doubling of net profit highlights improved cost management and higher margins relative to the previous year. The company’s earnings per share (basic and diluted) increased to ₹2.20 per equity share, up from ₹1.16 in the year-ago quarter. This growth in EPS underscores the enhanced value creation for shareholders driven by the stronger bottom-line performance.

Total comprehensive income for the period, comprising profit after tax and other comprehensive income, stood at ₹63.45 crore on a standalone basis, compared to ₹33.32 crore in Q1FY25. The reserves excluding revaluation reserve also saw an increase, rising to ₹1,803.12 crore as of June 30, 2026, from ₹1,662.02 crore at the end of the previous financial year.

What the Numbers Show

The data indicates a clear acceleration in profitability outpacing revenue growth. While revenue grew by roughly 36.7%, net profit surged by nearly 90%, suggesting significant operating leverage or favorable mix shifts within the product portfolio. The expansion in reserves by over ₹140 crore year-on-year further strengthens the balance sheet, providing a solid foundation for future capital allocation or debt reduction strategies.

IOL Chemicals & Pharmaceuticals submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Limited and BSE Limited on August 7, 2026. The filing, mandated under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company’s environmental, social, and governance performance. For FY26, the company reported a turnover of ₹2319.06 crore and a net worth of ₹1798.38 crore. The report highlights significant sustainability achievements, including 100% water neutrality and an 8.8% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared to FY25, despite a 43% increase in API production volumes.

The BRSR forms part of the company’s Integrated Annual Report for FY26 and was assured by Intertek India Private Limited, which provided reasonable assurance on the disclosures. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the submission. The report covers standalone operations, with the company maintaining one plant and three offices in India. Key business activities include the manufacturing of Active Pharma Ingredients and Intermediates, contributing 59.66% of turnover, and Specialty Chemicals, contributing 39.43%. Exports accounted for 24% of total turnover, serving markets in 70 countries.

Environmental Performance

IOL Chemicals & Pharmaceuticals reported total energy consumption of 2898 Tera Joules in FY26, comprising 2221.6 Tera Joules from renewable sources and 676.4 Tera Joules from non-renewable sources. Energy intensity per rupee of turnover was recorded at 0.000000125 Tera Joules. The company achieved 100% water neutrality, with total water withdrawal at 355,796 kilolitres and consumption at 355,796 kilolitres. A Zero Liquid Discharge process is implemented to treat, recycle, and reuse water in cooling towers.

Greenhouse gas emissions data reveals Total Scope 1 emissions of 60,731.8 metric tonnes of CO2 equivalent and Total Scope 2 emissions of 16,681.2 metric tonnes of CO2 equivalent. Total Scope 3 emissions were 85,528.6 metric tonnes of CO2 equivalent. The company noted that while absolute emissions rose due to production expansion, emission intensity decreased. Initiatives such as solar panel installation, waste-to-wealth projects, and supplier capacity building under the “Prayas” initiative contributed to these gains.

Social and Governance Highlights

The company employed 3,592 individuals as of the end of FY26, including 3,095 permanent employees. Women constituted 12.5% of the Board of Directors but held no positions in Key Management Personnel. The turnover rate for permanent employees was 16.00%. IOL Chemicals & Pharmaceuticals reported zero fatalities and one lost-time injury among employees during the year. The company maintains ISO 45001:2018 certification for occupational health and safety, covering 100% of its plants and offices.

Governance structures include a Corporate Social Responsibility Committee chaired by Rajender Mohan Malla. The company received two shareholder complaints in FY26, both resolved by year-end. No complaints were filed regarding sexual harassment, discrimination, or child labor. The company adheres to SA 8000:2014 social accountability standards and conducts regular training on human rights and ethical conduct for employees and value chain partners. Related party transactions accounted for 6.83% of purchases and 0.95% of investments, with no related-party sales or loans disclosed.